Comparison  	Comparison  	 NN	O
of  	of  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
risk  	risk  	 NN	I-NP
in  	in  	 IN	O
ankylosing  	ankylosing  	 JJ	B-NP
spondylitis  	spondylitis  	 NN	I-NP
and  	and  	 CC	O
rheumatoid  	rheumatoid  	 JJ	B-NP
arthritis  	arthritis  	 NN	I-NP
Cardiovascular  	Cardiovascular  	 NNP	I-NP
co-morbidity  	co-morbidity  	 NNP	I-NP
is  	is  	 VBZ	O
now  	now  	 RB	O
a  	a  	 DT	O
recognised  	recognised  	 JJ	B-NP
complication  	complication  	 NN	I-NP
of  	of  	 IN	I-NP
chronic  	chronic  	 JJ	I-NP
inflammation  	inflammation  	 NN	I-NP
and  	and  	 CC	O
an  	an  	 DT	O
elevated  	elevated  	 JJ	O
acute  	acute  	 JJ	O
phase  	phase  	 NN	O
response  	response  	 NN	O
predisposes  	predisposes  	 NN	O
to  	to  	 TO	O
hypertension 	hypertension 	 VB	O
,  	,  	 ,	O
stroke  	stroke  	 NN	O
and  	and  	 CC	O
myocardial  	myocardial  	 JJ	B-NP
infarction 	infarction 	 NN	I-NP
.  	.  	 .	O
Dyslipidaemia  	Dyslipidaemia  	 NNP	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
feature  	feature  	 NN	O
of  	of  	 IN	O
inflammatory  	inflammatory  	 JJ	B-NP
joint  	joint  	 JJ	I-NP
diseases  	diseases  	 NNS	I-NP
and  	and  	 CC	O
is  	is  	 VBZ	O
closely  	closely  	 RB	O
related  	related  	 VBN	O
to  	to  	 TO	O
elevated  	elevated  	 VB	B-NP
CRP  	CRP  	 NNP	I-NP
and  	and  	 CC	O
Il-6  	Il-6  	 CD	B-NP
levels 	levels 	 NNS	I-NP
.  	.  	 .	O
Rheumatoid  	Rheumatoid  	 JJ	B-NP
arthritis  	arthritis  	 NN	I-NP
( 	( 	 -LRB-	O
RA 	RA 	 NNP	B-NP
)  	)  	 -RRB-	O
has  	has  	 VBZ	O
an  	an  	 DT	O
increased  	increased  	 JJ	O
standardised  	standardised  	 JJ	B-NP
mortality  	mortality  	 NN	I-NP
ratio  	ratio  	 NN	I-NP
largely  	largely  	 RB	O
attributable  	attributable  	 JJ	O
to  	to  	 TO	O
cardiovascular  	cardiovascular  	 JJ	B-NP
risk 	risk 	 NN	I-NP
.  	.  	 .	O
An  	An  	 DT	O
increased  	increased  	 VBN	O
although  	although  	 IN	O
lesser 	lesser 	 JJR	O
,  	,  	 ,	O
cardiovascular  	cardiovascular  	 JJ	B-NP
morbidity  	morbidity  	 NN	I-NP
has  	has  	 VBZ	O
also  	also  	 RB	O
been  	been  	 VBN	O
observed  	observed  	 VBN	O
in  	in  	 IN	O
ankylosing  	ankylosing  	 JJ	B-NP
spondylitis  	spondylitis  	 NNS	I-NP
( 	( 	 -LRB-	O
AS 	AS 	 NNP	B-NP
)  	)  	 -RRB-	O
which  	which  	 WDT	O
has  	has  	 VBZ	O
a  	a  	 DT	O
similar  	similar  	 JJ	O
abnormal  	abnormal  	 JJ	O
lipid  	lipid  	 JJ	B-NP
profile  	profile  	 NN	I-NP
to  	to  	 TO	O
that  	that  	 DT	O
seen  	seen  	 VBN	O
in  	in  	 IN	O
RA 	RA 	 NNP	B-NP
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
some  	some  	 DT	O
evidence  	evidence  	 NN	O
that  	that  	 IN	O
therapeutic  	therapeutic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
such  	such  	 JJ	O
as  	as  	 IN	O
anti-tumour  	anti-tumour  	 JJ	B-NP
necrosis  	necrosis  	 JJ	I-NP
factor-alpha  	factor-alpha  	 NN	I-NP
( 	( 	 -LRB-	O
TNF-alpha 	TNF-alpha 	 NNP	B-NP
)  	)  	 -RRB-	O
drugs  	drugs  	 NNS	O
that  	that  	 IN	O
down-regulate  	down-regulate  	 JJ	O
the  	the  	 DT	O
acute  	acute  	 JJ	O
phase  	phase  	 NN	O
response 	response 	 NN	O
,  	,  	 ,	O
also  	also  	 RB	O
have  	have  	 VB	O
an  	an  	 DT	O
effect  	effect  	 NN	O
in  	in  	 IN	O
reducing  	reducing  	 VBG	O
cardiovascular  	cardiovascular  	 JJ	B-NP
complications  	complications  	 NNS	I-NP
in  	in  	 IN	O
RA  	RA  	 NNP	B-NP
and  	and  	 CC	O
AS 	AS 	 NNP	O
.  	.  	 .	O
